In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.

Dr. Christopher J. Hoimes, Associate Professor of Medicine-GU Oncology at Duke University, presents data on the KEYNOTE-045 Phase 3 Trial, which demonstrated that patients treated with KEYTRUDA (pembrolizumab) had a 27% reduction in risk of death compared to patients treated with chemotherapy.

Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), is indicated for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies. Based on the results of a clinical trial evaluating the long-term effects of the drug, the FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs. prescribing an alternative therapy.

Examining data on nearly half a million participants from the NIH-AARP Diet and Health Study revealed that individuals in the highest quintile of total fish intake had a 22% higher risk for malignant melanoma compared to those in the bottom quintile.

In this first part of a three-case series, a 65-year-old man received ruxolitinib for treatment and reported feeling much better after one month, and after two months of treatment, most of his symptoms had completely resolved and his blood cell counts were maintained under control.

Although the study did not meet its primary end point, the results of secondary analyses suggested a progression-free survival benefit with durvalumab plus olaparib in patients whose tumors harbor mutations in homologous recombination repair genes.